Physician profile
Frederick S Graham
NPI 1548212954
$4,474.79
in general payments reported to CMS, 2019-2025
33 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,780 · 2020: $585 · 2021: $887 · 2022: $553 · 2023: $272 · 2024: $267 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $1,055.12 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $578.35 | 2019-2025 | Xtampza, Belbuca |
| Medtronic USA, INC. | $469.75 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.34 | 2019-2025 | Relistor |
| Medtronic, INC. | $278.60 | 2021-2023 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $231.54 | 2019-2025 | Ztlido |
| Forte Bio-Pharma LLC | $223.54 | 2020-2024 | Prolate, Nalocet |
| Horizon Therapeutics Plc | $185.05 | 2019-2022 | |
| Almatica Pharma LLC | $172.17 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $105.70 | 2019-2021 | |
| Ibsa Pharma INC. | $89.56 | 2021-2022 | |
| Boston Scientific Corporation | $76.20 | 2019-2023 | Infinion 16 |
| Amgen INC. | $68.48 | 2021-2022 | |
| Pfizer INC. | $64.19 | 2019-2021 | |
| Assertio Therapeutics, INC. | $60.71 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $58.82 | 2019-2020 | |
| Redhill Biopharma INC. | $54.03 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $50.11 | 2022-2023 | Seglentis |
| Abbott Laboratories | $45.72 | 2022-2025 | Proclaim |
| Relievant Medsystems, INC. | $37.46 | 2021 | |
| Virtus Pharmaceuticals LLC | $34.38 | 2021-2023 | Levorphanol Tartrate |
| Grt US Holding, INC. | $33.64 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $29.91 | 2024 | Horizant |
| Nevro Corp. | $28.09 | 2024 | Senza |
| Stimwave Technologies Incorporated | $26.83 | 2019-2020 | |
| Curonix LLC | $26.03 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Avanos Medical | $22.08 | 2024 | Generator |
| Bioventus LLC | $17.47 | 2019 | |
| Shionogi INC | $17.00 | 2019 | |
| Baudax Bio INC. | $16.20 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.18 | 2019 | |
| Mdd US Operations, LLC | $11.40 | 2019 | |
| Si-Bone, INC. | $10.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.